Global Leukemia Therapeutics Market- By Type of Leukemia (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, and Other Types of Leukemia), By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, and Other Treatments), By Route of Administration (Oral Mode and Injectable Mode), By End User (Hospitals, Home Care, Specialized Clinics and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Other Distribution Channels), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

According to a recent report by Market.us, the Global Leukemia Therapeutics Market size is expected to be worth around USD 33.7 Billion by 2032 from USD 16.2 Billion in 2022, growing at a CAGR of 7.8% during the forecast period from 2023 to 2032.

Leukemia is a kind of blood malignant growth that happens because of transformation in the qualities capable of advancing white blood cells. The transformed qualities lead to the improvement of unusual WBCs in the bone marrow and cause leukemia. Other gamble factors that might cause leukemia include the family background of leukemia, smoking, exposure to synthetics or radiation, blood disorders, and hereditary issues, like Down syndrome.

There are various kinds of leukemia, with certain sorts happening all the more generally in youngsters and different sorts in the grown-up population. Chronic Myelogenous Leukemia (CML), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML) are a portion of the most generally happening types in the grown-up population. Then again, ALL happens in practically all age populations, including children, adults, and teenagers. The treatment for leukemia depends on its type and other contributing elements, like age, resistance limit regarding a particular type of treatment, and others.

*Actual Numbers Might Vary In The Final Report

Chemotherapy and designated treatment are some exceptionally favored treatment choices for leukemia as chemodrugs move through the circulation system to arrive at malignant growth cells across the body. This makes chemotherapy valuable for diseases like leukemia, particularly for individuals with acute lymphocytic leukemia. Medicines for targeted therapy directly attack cancer cells, hinder their growth in the body, and improve the patient’s treatment outcome.

Key Takeaways

• The Global Leukemia Therapeutics Market size is projected to reach USD 33.7 Billion by 2032.
• The market was valued at USD 16.2 Billion in 2022.
• The market is expected to grow at a CAGR of 7.8% from 2023 to 2032.
• Chronic lymphocytic leukemia (CLL) had a revenue share of 34.6% in 2022.
• The chemotherapy treatment segment is predicted to grow at a CAGR of 42% from 2023 to 2032.
• North America had a revenue share of 37.7% in 2022.
• GLOBOCAN 2020 reported 475,000 cases of leukemia worldwide in 2020, expected to rise to 692,000 cases by 2040.
• In 2021, 397,501 Americans were either in remission or living with leukemia.
• The American Cancer Society reported an estimated 59,610 cases of leukemia with 23,710 fatalities.
• Chronic lymphocytic leukemia (CLL) segment dominated with 34.6% of the market.
• The chemotherapy segment’s projected market share is 42%.
• The injectable route of administration held the highest market share in the market.
• The hospitals segment generated the most revenue in end-users.
• In June 2023, Medicines Patient Pool (MPP) signed an agreement with four pharma companies for Tasigna.
• Pfizer gained FDA approval for Elrexfio in August 2023.

Type of Leukemia Analysis

The CLL Segment held a Dominant Share of the Market

The market can be segmented into CML, CLL, ALL, AML, and others. The Chronic Lymphocytic Leukemia segment commanded most of the market share at 34.6%. Due to a large patient base and rising demand for CLL treatments, this disease dominates the market. The National Cancer Institute estimates that approximately the majority of new cases of blood cancer will be diagnosed in the United States in the upcoming years, driving market expansion.

With a large population base in the United States and Europe, the acute myeloid leukemia segment is the second-largest type of market. The chronic myeloid leukemia CML segment is the third largest market after AML. CML is less common in developing countries like India and other Asian nations than in Western nations. Due to a small patient base, the acute lymphocytic leukemia ALL segment has the lowest market share.

Treatment Analysis

The Chemotherapy Segment is Anticipated to Dominate the Market During the Forecast Period

The market is segmented into chemotherapy, targeted therapy, and immunotherapy. Since chemotherapy is the first line of treatment for leukemia and results in successful treatment outcomes for the patient, it is anticipated that the chemotherapy segment will dominate the market with 42% of the market share during the forecast period.

The segment is also expanding due to the increasing number of new chemotherapy products for leukemia treatment. For instance, the oral chemotherapy drug Onureg was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with newly diagnosed AML. Due to its effectiveness and improved patient outcomes, targeted therapy is the fastest-growing market segment.

Immunotherapy ranks third in terms of treatment type because it causes the patient’s immune system to be activated to aid in killing cancer cells. The FDA has approved ten immunotherapy options for leukemia that support segmental growth.

The other market, which includes adoptive cell therapy and radiotherapy, is anticipated to expand at the lowest CAGR.

Route of Administration Analysis

The Injectable Segment Accounted for The Largest Market

The leukemia therapeutics market was segmented into oral and injectable. Due to the availability of many drugs in injectable forms, such as chemotherapy and targeted therapy, the injectable segment held the largest market share. It was the most widely used mode of administration.

They are increasingly preferred because injectable medications are easy for the body to absorb and deliver rapid results. Due to its convenience and safety, the oral route of administration is expected to be the second-largest segment during the forecast period. This route of administration avoids pain.

End User Analysis

Hospital Segments Continues to Generate the Most Revenue

By End-users the leukemia therapeutics market can be bifurcated into 4 segments, namely, Hospitals, Home Care, Specialized Clinics and Others. The hospital segment generates the most revenue and thus is the largest contributor to the market. The Home care segment is expanding at a considerable rate as well. Alternatively, throughout the forecast, specialized clinics are predicted to experience exponential growth with a high CAGR.

Distribution Channel Analysis

The Hospital Pharmacy Segment Is Expected to Account for The Highest Share

The market was segmented into hospitals, retail, and other pharmacies. Throughout the forecast, it is anticipated that the hospital pharmacy sector will hold most of the global market. Hospitals provide the majority of treatments. Hospital pharmacies have grown due to the growing number of patients seeking treatment and diagnosis there.

The retail pharmacy sector is anticipated to hold the second-largest market share during the forecast period. It is now in second place by distribution channel due to the small number of retail pharmacies that sell leukemia treatment products in developing nations.

Online pharmacies are included in the other market segment, expanding at the lowest CAGR. Segmental growth is slowed by the limited product selection on online platforms for leukemia treatment.

Key Market Segments

Based on the Type of Leukemia

• Chronic Lymphocytic Leukemia
• Acute Myeloid Leukemia
• Acute Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Other Types of Leukemia

Based on Treatment

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Other Treatments

Based on the Route of Administration

• Oral Mode
• Injectable Mode

Based on the End Users

• Hospitals
• Home Care
• Specialized Clinics
• Others

Based on Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels

Drivers

The Increasing Prevalence of Leukemia Across the Globe

The rising incidence of leukemia worldwide, which is anticipated to increase demand for leukemia therapeutics, is one of the primary driving forces in the global market. Worldwide, almost all types of leukemia, including ALL and CML, are experiencing an increase in significance.

For instance, estimated millions of people in the United States will be diagnosed with leukemia, as stated in figures released by the Leukemia & Lymphoma Society (LLS). In a similar vein, the International Agency for Research on Cancer predicted that a large number of new cases of leukemia would be identified worldwide. An increase in global patient populations is anticipated to accelerate market expansion.

Restraints

Side Effects and Adverse Reactions Associated with The Products

Despite their benefits, the enhancement of the global market for leukemia treatment products is likely constrained by their associated side effects and adverse reactions. Chemotherapy, for example, can cause various side effects, including infections, hair loss, high BP, skin issues, fatigue, and other symptoms.

Similarly, adverse reactions to targeted therapies can include problems with diarrhea, liver, nausea, hair loss, and vomiting. Additionally, certain side effects of other treatments, such as radiotherapy, may decrease the use of leukemia therapeutic products.

Opportunities

Innovation in leukemia reseach is of the essene due to the debilitating nature of the disease. Patient outcomes are influenced by interdisciplinary approach to treatment, patient-centred communication and efficient decision making. An interdisciplinary approach to leukemia research can be promising.

Further with the increased awareness and implementation of targeted therapy for leukemia, the patient outcomes in general have been regarded as favourable. This avenue of treatment should be explored to enhance the quality of therapeutics for leukemia patients.

Impact of Macroeconomic Factors

The soaing inflation rates have considerably affected the leukemia therapeutics market. Prices of medical products and services rises with inflation. Leukemia patients are much more vulnerable to inflation, seeing that leukemia therapy is quite expensive and at times inaccessible to begin with.

According to International Monetary Fund, rate of inflation is expected to fall down to 4.1% by the year 2024. This forecast is promising for leukemia patients since it suggests a decrease in healthcare costs.

Latest Trends

Development of Novel Treatments for Leukemia Supports the Market Growth

To improve patient outcomes for various types of leukemia, various research activities are being carried out to develop various treatment strategies that employ combinations of various therapies. Combining cytarabine and anthracycline drugs with chemotherapy is the new approach to improving patient outcomes. Although chemotherapy is considered the first line of treatment, companies are developing immune therapies for this disease because many patients are resistant to certain chemotherapy drugs.

Chemoresistant B cell acute myeloid leukemia (AML) and acute lymphoblastic leukemia (BALL) are being treated with new immune-based therapies like immune checkpoint blockers (ICBs), CAR T cells, and bi-specific T cell engagers (BiTEs). This market’s emerging stem cell therapies, trends, and bone marrow transplants are anticipated to boost growth.

Natural killer cell-based immunotherapy for AML is also one treatment option for addressing clinical needs that have not been met. Additionally, a high-reliability artificial intelligence (AI) tool for tracking and detecting acute myeloid leukemia has been developed by the DZNE and the University of Bonn research teams. Creating cutting-edge treatments and diagnostics for people with leukemia is anticipated to boost market expansion.

Regional Analysis

North America Dominates the Global Leukemia Therapeutics Market During the Forecast Period

The global market is segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East & Africa. North America accounted for the highest revenue share at 37.7%. Cases from North America are responsible for the region’s global market dominance. For instance, the American Cancer Society estimates that more than a maximum of people in the United States will be diagnosed with CML, supporting market expansion in this region.

Due to the growing number of people with leukemia and the increased use of cutting-edge therapeutics, the European market is expected to be the second largest. Due to the large patient population and increasing product launches in developing nations like India, China, and others, APAC is anticipated to be the fastest-growing region over the forecast period. Furthermore, reimbursements for cancer treatments aid this region’s market expansion.

The other regional markets are the Middle East, Africa, and Latin America. Though they had a smaller market share, they are estimated to grow strongly during the forecast period due to increased awareness of leukemia treatment and higher healthcare costs.

Key Regions

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Factors Analysis

Novartis AG and Bristol-Myers Squibb Company Dominated the Global Market

The global market is characterized by the dominance and presence of a few key companies in the competitive scenario. In the current competition environment, Novartis AG and Bristol-Myers Squibb Company commanded a significant global market revenue share. The diverse product categories in their robust product portfolio of leukemia therapeutics account for these market leaders’ dominance. For instance, Novartis AG’s well-known treatment for CML, Tasigna, has helped it dominate the global market.

Top Key Players

Listed below are some of the most prominent players in the global leukemia therapeutics market.

• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• Other Key Players

Recent developments

• May 2023: Bristol-Myers Squibb Co. disclosed the primary results of Phase 1/2 of the Breyanzi study. The drug is intended to treat relapsed patients with chronic lymphocytic leukemia (CLL).
• August 2023: Talvey, a pioneering drug for multiple mylenoma, received conditional approval from the FDA. The medicine is the second bispecific antibody developed by Johnson & Johnson. It is a first of its kind drug since it binds to CD3 and GPRC5D, which are proteins found on T-cells and malignant blood plasma cells.

Report Scope